Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Imagion Biosystems has initiated manufacturing of its MagSense imaging agent for its phase II clinical study on HER2+ breast cancer, an essential requirement for filing an Investigational New Drug ...

Bryan O’Donnell, Head of Quality at Gaelic Laboratories, explains how to navigate GMP challenges to ensure your company ...

Mary Kay Bates, senior global cell culture scientist at Thermo Fisher Scientific, explores best practices for implementing ...

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of ...

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

In the realm of men’s health, maintaining optimal vitality, stamina, and confidence is paramount. With the increasing pace of ...